Hydrogel-mediated DOX·HCl/PTX delivery system for breast cancer therapy

Hoon Hyun; Young Bum Yoo; So Yeon Kim; Hyun Sun Ko; Heung Jae Chun; Dae Hyeok Yang

doi:10.3390/ijms20194671

Hydrogel-mediated DOX·HCl/PTX delivery system for breast cancer therapy

Hoon Hyun
, Young Bum Yoo
, So Yeon Kim
, Hyun Sun Ko
, Heung Jae Chun
, Dae Hyeok Yang

Research output: Contribution to journal › Article › peer-review

19 Scopus citations

Abstract

We used a hydrogel-mediated dual drug delivery approach, based on an injectable glycol chitosan (GC) hydrogel, doxorubicin hydrochloride (DOX·HCl), and a complex of beta-cyclodextrin (β-CD) and paclitaxel (PTX) (GDCP) for breast cancer therapy in vitro and in vivo. The hydrogel was swollen over 3 days and remained so thereafter. After an initial burst period of 7 hours, the two drugs were released in a sustained manner for 7 days. The in vitro cell viability test showed that GDCP had a better anticancer effect than well plate and DOX·HCl/PTX (DP). In addition, the in vivo tests, which evaluated the anticancer effect, systemic toxicity, and histology, proved the feasibility of GDCP as a clinical therapy for breast cancer.

Original language	English
Article number	4671
Journal	International Journal of Molecular Sciences
Volume	20
Issue number	19
DOIs	https://doi.org/10.3390/ijms20194671
State	Published - 1 Oct 2019

Bibliographical note

Publisher Copyright:
© 2019 by the authors. Licensee MDPI, Basel, Switzerland.

Keywords

Beta-cyclodextrin
Breast cancer therapy
Doxorubicin hydrochloride
Injectable glycol chitosan
Paclitaxel

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/ijms20194671

Cite this

@article{fae09232140c4777966ebc2bd22995d6,

title = "Hydrogel-mediated DOX·HCl/PTX delivery system for breast cancer therapy",

abstract = "We used a hydrogel-mediated dual drug delivery approach, based on an injectable glycol chitosan (GC) hydrogel, doxorubicin hydrochloride (DOX·HCl), and a complex of beta-cyclodextrin (β-CD) and paclitaxel (PTX) (GDCP) for breast cancer therapy in vitro and in vivo. The hydrogel was swollen over 3 days and remained so thereafter. After an initial burst period of 7 hours, the two drugs were released in a sustained manner for 7 days. The in vitro cell viability test showed that GDCP had a better anticancer effect than well plate and DOX·HCl/PTX (DP). In addition, the in vivo tests, which evaluated the anticancer effect, systemic toxicity, and histology, proved the feasibility of GDCP as a clinical therapy for breast cancer.",

keywords = "Beta-cyclodextrin, Breast cancer therapy, Doxorubicin hydrochloride, Injectable glycol chitosan, Paclitaxel",

author = "Hoon Hyun and Yoo, \{Young Bum\} and Kim, \{So Yeon\} and Ko, \{Hyun Sun\} and Chun, \{Heung Jae\} and Yang, \{Dae Hyeok\}",

note = "Publisher Copyright: {\textcopyright} 2019 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2019",

month = oct,

day = "1",

doi = "10.3390/ijms20194671",

language = "English",

volume = "20",

journal = "International Journal of Molecular Sciences",

issn = "1661-6596",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "19",

}

TY - JOUR

T1 - Hydrogel-mediated DOX·HCl/PTX delivery system for breast cancer therapy

AU - Hyun, Hoon

AU - Yoo, Young Bum

AU - Kim, So Yeon

AU - Ko, Hyun Sun

AU - Chun, Heung Jae

AU - Yang, Dae Hyeok

PY - 2019/10/1

Y1 - 2019/10/1

N2 - We used a hydrogel-mediated dual drug delivery approach, based on an injectable glycol chitosan (GC) hydrogel, doxorubicin hydrochloride (DOX·HCl), and a complex of beta-cyclodextrin (β-CD) and paclitaxel (PTX) (GDCP) for breast cancer therapy in vitro and in vivo. The hydrogel was swollen over 3 days and remained so thereafter. After an initial burst period of 7 hours, the two drugs were released in a sustained manner for 7 days. The in vitro cell viability test showed that GDCP had a better anticancer effect than well plate and DOX·HCl/PTX (DP). In addition, the in vivo tests, which evaluated the anticancer effect, systemic toxicity, and histology, proved the feasibility of GDCP as a clinical therapy for breast cancer.

AB - We used a hydrogel-mediated dual drug delivery approach, based on an injectable glycol chitosan (GC) hydrogel, doxorubicin hydrochloride (DOX·HCl), and a complex of beta-cyclodextrin (β-CD) and paclitaxel (PTX) (GDCP) for breast cancer therapy in vitro and in vivo. The hydrogel was swollen over 3 days and remained so thereafter. After an initial burst period of 7 hours, the two drugs were released in a sustained manner for 7 days. The in vitro cell viability test showed that GDCP had a better anticancer effect than well plate and DOX·HCl/PTX (DP). In addition, the in vivo tests, which evaluated the anticancer effect, systemic toxicity, and histology, proved the feasibility of GDCP as a clinical therapy for breast cancer.

KW - Beta-cyclodextrin

KW - Breast cancer therapy

KW - Doxorubicin hydrochloride

KW - Injectable glycol chitosan

KW - Paclitaxel

UR - https://www.scopus.com/pages/publications/85072574911

U2 - 10.3390/ijms20194671

DO - 10.3390/ijms20194671

M3 - Article

C2 - 31547111

AN - SCOPUS:85072574911

SN - 1661-6596

VL - 20

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

IS - 19

M1 - 4671

ER -

Hydrogel-mediated DOX·HCl/PTX delivery system for breast cancer therapy

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this